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ABSTRACT
The thyroid hormone receptor (TR) and the retinoic acid
receptor (RAR) induce gene expression in the presence
of specific ligand and repress transcription in the
absence of hormone. This repression is mediated by
an active silencing mechanism rather then by
interference with DNA binding activators. V-erbA, a
variant form of TR which is unable to bind hormone,
represents a constitutive repressor. Here we show,
using fusion proteins with the GAL4 DNA binding
domain, that the minimal silencing domain of v-erbA
extends from amino acids 389 to 632 and that internal
deletions within this domain retain at least some
repression function. Co-transfection experiments of
different deletion mutants indicate that the silencing
domain is composed of at least two sub-domains which
are non-functional when tested individually. When
combined in a heterodimeric complex, they synergize
such that silencing activity is regained. In contrast to
the retinoic acid receptor the retinoid X receptor does
not contain a silencing domain. In addition it is unable
to cooperate with the repression function of TR or v-
erbA in a heterodimer.
INTRODUCTION
The members of the thyroid hormone receptor (TR) and of the
retinoic acid receptor (RAR) family act on vertebrate development
and homeostasis by binding to specific DNA sequences (1-3),
thereby regulating transcription of target genes (4,5).
TR and RAR are ligand inducible transcription factors which
repress transcription in the absence of hormone and induce
expression in the presence of specific ligand (6). Depending on
the promoter context or type of response element ligand
dependent repression has been described as well (7-10). Here
we are analyzing the repression in the absence of ligand which
is mediated by an active silencing mechanism even acting on a
minimal promoter composed of only a TATA box (1 1). Variant
forms of these factors which are unable to bind hormone represent
constitutive repressors (6,12). Recently the analysis of thyroid
hormone resistance syndrome patients illustrated the importance
of this repression function. A dominant negative TR mutant is
causing a severe impairment of physical and mental development,
which is not seen upon TR gene deletion (13). Similarly, a major
role for silencing is demonstrated by the chicken oncogene
product v-erbA. It does not bind T3 due to mutations in its ligand
binding domain (14), it functions as a constitutive silencer protein
(6,11,12,15) and it interferes with normal erythropoiesis
(16-20). A natural mutant of v-erbA (Pro 399 to Arg) lacks
the oncogenic and the silencing activity (21,22).
Deletion analysis of v-erbA assigned the silencing function to
about 300 C-terminal amino acids (a.a.) of the protein (23).
Corresponding domains of TR and RAR were able to mediate
both, repression and ligand dependent induction. In contrast to
other repression mechanisms (7-9,24-27), nothing is known
about the structural requirement for silencing domains, a
prerequisite for the mechanistic understanding of this effect (24).
The finding that both TR and RAR as well as other members
of the gene family form heterodimers with RXRs adds even more
complexity to the transcription regulation by these factors
(28 -34). The natural ligand for RXR was shown to be 9-cis
retinoic acid (9-cis-RA), a stereoisomer of all-trans-retinoic acid,
the ligand for RAR (35,36). Heterodimerization ofTR with RXR
strongly enhances both, specific DNA binding measured in vitro
(28,30,37,38) and transcriptional induction in transient
transfection experiments (31,32,34,39) or in vitro (40). It was
not known whether RXR exhibits or contributes to the repression
function in the ligand free heterodimer with TR or RAR.
Here we show that the v-erbA silencing domain is composed
of at least two regions, both of which are non functional on their
own. Repression activity is restored when both regions are present
in one protein, but interestingly also when present on two different
proteins which are able to form heterodimers.
We find that a region of the RXR domain, corresponding to
the minimal silencing domain of v-erbA, does not mediate
transcriptional repression, although it readily displays hormonal
induction. In addition it does not contribute to TR or v-erbA
silencing when present in a heterodimer.
RESULTS
V-erbA contains a large silencing domain
Based on previous results (23) we wanted to define more precisely
regions of v-erbA required for transcriptional repression.
Therefore we fused the C-terminal part of v-erbA to the
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heterologous DNA binding domain (DBD) of the yeast activator
GAL4. Amino acids 1-147 of GAL4 are sufficient for mediating
several functions such as nuclear translocation, dimerization and
binding to the specific upstream activator sequence (UAS),
whereas the major trans-activation functions are deleted.
Transcriptional regulation mediated by GAL4-DBD or by the
chimeric proteins was measured using a reporter plasmid carrying
the bacterial chloramphenicol acetyl transferase (CAT) gene.
CAT expression was under the control of a GAL4 DNA binding
site upstream of the thymidine kinase (tk) promoter. This
approach allows to study the function of v-erbA domains
independently of endogenous members of the thyroid hormone
receptor family which bind to the T3 response elements, but not
to an UAS. Expression and DNA binding ability was tested by
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Figure 1. Amino-terminal deletion mapping of the v-erbA silencing domain.
Expression vectors coding for the indicated fusion proteins were transfected into
Ltk- cells together with the indicator plasmid UAS-tkCAT (top line). Fold
repression was calculated from CAT activities obtained in triplicate transfections
relative to the CAT activity seen after co-transfection of a non-coding expression
vector and the reporter plasmid (23 2% CAT conversion). Experiments were
repeated at least twice.
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Figure 2. Internal deletions of the v-erbA silencing domain. Expression vectors
coding for the indicated fusion proteins were transfected into Ltk- cells together
with the indicator plasmid UAS-tkCAT (see legend to Fig. 1). Expression of
UAS-tkCAT together with a non-coding expression vector was 40 X 3% CAT
conversion.
Figure 3. (a) Formation of heterodimers after cotransfection of different expression
vectors. Fusion proteins GAL-erb 362-468/508-639 or GAL-erb 362-508 were
expressed in COSI cells either alone (lanes A or B, respectively) or together in
one experiment (ane A +B). Cell extracts were used in a gel retardation experiment
using an UAS probe and the autoradiogram was scanned in order to determine
migration differences of the protein-DNA complexes. The lanes were analysed
using the Bio-image software and the density profile is displayed. Each band is
connected to the corresponding peak in the profile. A:A, B:B and A:B indicate
the positions of the A homodimer, the B homodimer and the A+B heterodimer,
respectively. S indicates the slot, U an unspecific band and F the free probe.
(b) GAL-erb fusion proteins interact in vitro: GST-Fusion proteins GST-GAL-
erb 508-639, GST-erb 508-639 and GST-erb 362-508 and GST alone were
expressed in bacteria, bound to Glutathione- Sepharose beads and incubated with
the indicated in vitro translated, 35S labelled proteins. The beads were washed,
specifically bound proteins were analysed on SDS-PAGE and visualised by
Fluorography. Lanes 4, 7, 8, 9, 10, 13 (input) show the in vitro labelled proteins
utilised, luciferase was added in the interaction reaction as specificity control.
The arrows indicate the positions of the correctly translated proteins: GAL-
erb 362-508 (N), luciferase (L), GAL-erb 409-639 (C), GAL-
erb 362-468/508-639 (A) and GAL-erb 508-639 ( ).
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gel retardation experiments and found to be similar for all the
mutants (23 and data not shown).
Transfection of an expression vector coding for the
GAL4-DBD had no effect on UAS driven CAT expression in
Ltk- cells (Fig. 1). In contrast, as we have previously shown,
expression of a fusion protein containing GAL4-DBD and v-erbA
amino acids 346-639 (GAL-verbA) led to 100-fold repression
of the basal transcription rate. N-terminal deletion in the v-erbA
domain of 16 a.a. (GAL-erb 362-639) or of 43 a.a. (GAL-
erb 389-639) did not reduce the silencing function, in fact a
slight but reproducible increase of the repression was detected.
Deletion of additional 20 a.a. abolished silencing (GAL-
erb 409-639). Interestingly, in this mutant prolines 397 and 399
were deleted, one of which (Pro 399) is exchanged in a natural
mutant which is inactive (21). It was previously shown that the
C-terminal deletion of 7 a.a. (346-632) retains repression
function, whereas further deletion (346-616) severely reduces
silencing (23). These results define the minimal silencing domain
of v-erbA spanning a.a. 389 to 632.
In order to further define structural features involved in
transcriptional silencing, we constructed internal deletion mutants
in the v-erbA silencing domain and compared their repression
activity relative to the complete domain (Fig. 2). Deletion of a.a.
435 to 467 (GAL-erb 362-434/468-639) or a.a. 516 to 614
(GAL-erb 346-515/615-639) abolishes repression. Deletion of
a.a. 390 to 433 (GAL-erb 346-389/434-639) or of a.a. 469
to 507 (GAL-erb 362-468/508-639) reduced silencing activity
to about 6% of the repression conferred by the wild type protein.
This residual activity suggests that some functional features
remain intact, which might be explained by the presence of
subdomains.
Silencing subdomains can synergize
For further characterization we analyzed silencing subdomains
for possible functional complementation. Therefore we made use
of the dimerization interface of the GAL4-DBD. Expression of
two different GAL4 fusion proteins in a cell leads to formation
of heterodimers between the two chimeric proteins, as visualized
in gel retardation experiments (Fig. 3a). Whole cell extracts from
COSI cells transfected with GAL-erb 362 -508 (see Fig. 4) or
GAL-erb 362-468/508 -639 expression vectors formed a
Expressionplasmid A A A+B
corresponding DNA-protein complex with an UAS probe (lane
A or B). Co-expression of both chimeric proteins leads to the
formation of an intermediary complex consisting of a heterodimer
(Fig. 3a, lane A+B).
To further prove the formation of heterodimers via the
GAL4-DBD, an independent in vitro assay was performed.
Fusion proteins with the Glutathione-S-transferase were
bacterially expressed, bound to Glutathione-Sepharose and used
to precipitate specifically interacting in vitro translated, 35S-
labelled proteins (input Fig. 3b, lanes 4, 8, 10, 13). In each
experiment in vitro translated, 35S-labelled luciferase (L) (input
Fig. 3b, lanes 7 and 9) was added as a specificity control. When
GST-GAL-erb 508 -639 was coupled to the beads, interaction
could be detected with labelled GAL-erb 508 -639 (lane 14),
GAL-erb 362-468/508-639 (lane 11), GAL-erb 409-639
(lane 6) and GAL-erb 362-508 (lane 3). When only GST was
used no radioactive band was visible (lanes 2, 5, 12, 15). In
addition, luciferase was not retained in any of these experiments,
indicating that the protein-protein interactions are specific. The
interaction was mediated by the dimerisation function of the
GAL4-DBD, as the fusion proteins GST-erb 508 -639 or GST-
erb 362-508 did not interact with GAL-erb 508-639 (lane 16)
or GAL-erb 362 -508 (lane 1), respectively.
In order to measure the effect of heterodimers on UAS-driven
transcription, we compared the reporter gene activity after co-
expression of two fusion proteins to the reference transcription
obtained with a single protein. To avoid differences in the
transfection and expression conditions, we added equal amounts
of GAL4-DBD expression plasmid in the reference transfection
as well. This allows a direct comparison of the effects due to
GAL4-DBD/GAL-fusion protein heterodimers (in the reference
transfection) to those mediated by GAL-fusion A/GAL-fusion
B heterodimers (in the co-expression experiment).
Reference expression of GAL-erb 362-508 or GAL-
erb 409-639 is deficient in silencing. Co-expression of both
fusion proteins leads to a 2.6-fold repression of CAT transcription
(Fig. 4, line 1). Heterodimers between GAL-erb 362-508 and
GAL-erb 508-639 showed a clear 6-fold synergistic repression
as opposed to the reference transfections (line 2). Further N-
terminal deletion of the silencing domain in Gal-erb 557 -639
and Gal-erb 617 -639 resulted in loss of the complementation
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Figure 4. Synergism between v-erbA subdomains in heterodimers. Expression vectors coding for the indicated fusion proteins were co-transfected with the UAS-
tkCAT reporter plasmid into Ltk- cells either together with a GAL4-DBD expression vector (columns A or B) for reference expression or together with a vector
for a second fusion protein (column A+B) for synergistic silencing. Numbers indicate fold repression relative to transfection of a GAL4-DBD expression vector
with the UAS-tkCAT reporter (28 i5% CAT conversion).
Nucleic Acids Research, 1994, Vol. 22, No. 23 4901
activity (lines 3 and 4). These data show that the silencing domain
of v-erbA is composed of at least two regions which are non-
functional when tested individually, but which can complement
each other even when placed on two different proteins capable
to form heterodimers.
In order to ensure that the complementation effect is not due
to a higher amount of GAL-verbA fusion proteins in comparison
to the reference transfection, we tested combinations of
heterodimeric partners containing identical putative silencing
regions. Neither of these combinations led to significant
repression (Fig. 4, lines 5+6). In addition, increasing the amount
of transfected GAL-erb 362-508 in the absence of a second
expression vector did not result in silencing (data not shown).
Furthermore, we were interested to know whether a deletion
mutant mediating residual silencing activity could synergize with
other subdomains. Therefore we tested GAL-erb 362-468/
508-639. The repression function of this fusion protein is
dramatically increased when co-expressed with different
heterodimeric partners (Fig. 5). Both, the N-terminal v-erbA
subregion (GAL-erb 362-508) or the C-terminal region (GAL-
erb 409-639) fused to the GAL4-DBD synergize efficiently in
silencing activity with GAL-erb 362-468/508-639 (Fig. 5).
One of these combinations (Fig. 5, line 1) yields near to wild
type activity. Another internal deletion mutant with a severe defect
in silencing, GAL-erb 362-434/468-639, was unable to com-
plement GAL-erb 362-508 (Fig. 5, line 3).
We conclude that the silencing domain of v-erbA is composed
of two subdomains (I+11), both of which are non functional when
tested individually, but which can synergize to restore activity
even when placed on two different heterodimeric partners. Sub-
domain I includes a.a. 389 to 508. Position 389 is determined
Expressionplasmid A A A+B
from Figure 1, and position 508 from plasmid A in Figure 4,
line 1. Subdomain II contains a.a. 508 to 632. Position 508 is
suggested by plasmid B in Figure 4, lines 1 and 2 and position
632 from previous deletions tested in homodimeric GAL fusions
(23).
The retinoic acid X receptor (RXR) does not mediate
transcriptional silencing
Other members of the nuclear receptor family closely related to
v-erbA, like TR and RAR, show silencing activity in the absence
of their specific ligands (6,23). The carboxyterminal domains
of TR and RAR are 90 and 30% homologous to v-erbA,
respectively. Since the corresponding domain of the retinoid X
receptor (RXR) is 27% homologous to the silencing domain of
RAR and since RXR is a regular component of the TR or RAR
transcription complex, we wanted to know whether RXR confers
a silencing function as well. Since the negative regulation was
more pronounced using GAL4-DBD fusion proteins, we joined
the C-terminal part (a.a. 235 -462) of RXR to this heterologous
DNA binding domain. The transcriptional effect on an UAS-
driven tk-CAT gene of this chimeric protein in the presence or
absence of ligand was tested and compared to the previously
described regulation mediated by GAL-TR or GAL-verbA (23).
In order to avoid interference with endogeneous factors, we used
CVI cells devoid of most of the nuclear receptors. Expression
of the GAL4-DBD shows no effect, expression of GAL-TR leads
to clear repression in the absence ofhormone and clear induction
in the presence of hormone (Fig. 6) and GAL-verbA displays
a constitutive silencing function, as expected. In comparison to
L-cells the CVI cells show less silencing activity. GAL-RXR
mediates induction upon addition of retinoic acid, but no, or a
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Figure 5. Synergism of v-erbA subdomains with internal deletion mutants. Expression vectors coding for the indicated fusion proteins were transfected into Ltk-
cells either together with a GAL4-DBD expression vector (columns A and B) for reference expression on a UAS-tkCAT reporter plasmid or together with a vector
for another fusion protein (column A+B) for synergistic silencing. Expression of UAS-tkCAT together with a GAL4-DBD expression vector was 46 2% CAT conversion.
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Figure 6. GAL-RXR mediates hormonal induction, but not silencing in the absence of ligand. Expression vectors coding for the indicated fusion proteins were transfected
into CVI cells together with the indicator plasmid UAS-tkCAT. Fold induction of CAT-activity in the presence of hormone and fold repression in the absence of
hormone are calculated relative to expression of GAL4-DBD.
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: ~~~erb 346-389/434-639 and GAL-erb 362-468/508-639)
retain some of the repressing function suggests that the silencing
domain is composed of at least two functional domains. A final
' proof is given by the co-transfection experiments, generating
heterodimers containing the putative subdomains on different
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do not restore silencing function when cotransfected (see Fig.
UAS-tkCAT 4, lane 5). The dimerization interface is contributed by the
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(Fig. 3b, lanes 1 and 16). Gel retardation experiments using
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not lead to repression. Heterodimers formed between GAL-
erb 362/508 and GAL-erb 508-639, which contain perfectly
complementary sequences of the silencing domain, showed a
strong synergistic silencing effect. Similarly the repression
function of GAL-erb 362-468/508-639, a weakly functional
mutant can be restored to nearly wild type by co-expression of
several deletion mutants.
The results obtained using the internal deletion mutants and
the heterodimeric complexes point to region 434-468 as being
absolutely required for function. It has to be present in at least
one of the heterodimeric partners. Deletion of only these amino
acids in GAL-erb 346-434/468-639 leads to a non-functional
protein (Fig. 2, line 3), which cannot be complemented by a
fusion protein (GAL-erb 362-508, Fig. 5, line 3) shown to
synergize in other cases (Fig. 4, lines 1 and 2).
Recently, synergism in silencing between two non-functional
subdomains of the hTR(3 C-terminal region was described using
GAL4 fusion proteins and a reporter gene containing four UAS
binding sites (42). In our system, using a single UAS, co-
expression of the corresponding v-erbA fusion proteins GAL-
erb 362-439 and GAL-erb 409-639 led to a weak, but
reproducible synergism as well.
Synergism between transcriptional activating domains is a
general phenomenon. Steroid receptors contain two or more trans-
activation domains cooperating for full activity (43 -45). In case
of the human estrogen receptor two activation functions AF1 and
AF2 were shown to synergize when present on different DNA
binding entities (45). Recently the transcription factor TEF1 was
shown to require at least two out of three subdomains for
activation function, each of which is inactive when tested
individually in a GALA fusion protein (46). Synergism within
a heterodimer was described for the hormone dependent activation
by RXR/RAR complexes (29,30,31,33,39). It was shown that
heterodimers formed of one partner containing the N-terminal
AF1 domain and the other partner containing the C-terminal AF2
domain displayed synergistic activation function (47). This
synergism was also seen if one of the partners lacks a
corresponding binding site in the regulated promoter. Specific
synergistic silencing was described for v-erbA or TR with the
protein Nepl binding close to a thyroid hormone responsive
element in the chicken lysozyme silencer -2.4 kb (11,48). Here
we describe a synergism between two silencer subdomains.
The mechanism for this synergism is still unclear. Direct
interaction of hTRa 1 (49) and the C-terminus of hTR(3 (42) with
TFIIB has been demonstrated. This interaction is relieved in the
presence of T3 (42), suggesting that this interaction may be
involved in the silencing activity. The region of hTR(3 interacting
with TFIIB corresponds roughly to the synergising subdomain
A.A. 508 -639 of v-erbA. Whether the complementary domain
389-508 interacts with some other component of the transcrip-
tion pre-initiation complex remains to be shown.
V-erbA and ligand-free TR and RAR are able to mediate
silencing. RAR and TR have been shown to function in a
heterodimeric complex with RXR. In addition RXR is closely
related to TR and RAR. Therefore we wanted to know whether
RXR exhibits a silencing function of its own and/or whether RXR
synergizes in repression with one or both of the silencing domains
of v-erbA in a hetero-complex. The C-terminal fragment of RXR,
corresponding to the minimal v-erbA silencing domain, is able
to mediate the RA inducibility in the chimeric protein GAL-RXR,
but does not show any silencing activity. Usually we observe
then the natural proteins on their specific binding site (23). We
therefore conclude that the hRXRa does not contain a transferable
silencing function. In addition, we could show that GAL-RXR
in heterodimers with GAL-TR or with GAL-verbA, respectively,
does not influence their repression activity in the absence of any
ligand. Only addition of RA leads to an increase of CAT
transcription, due to the ligand-induced GAL-RXR.
MATERIALS AND METHODS
Plasmids
The reporter plasmid used in this study contains a GAL4 binding
site (17mer)(50) inserted in front of the tkCAT gene (23).
The expression vectors pABGAL, pAB-GAL, pGAL-erbA
A346, pGAL-erb 362-639, pGAL-erb 409-639, pGAL-erb
508 -639, pGAL-erb 557 -639, pGAL-erb 617 -639, pGAL-
erb 362-508, pGAL-erb 360-439, pGAL-erb 362-468/
508-639, pGAL-erb 362-434/468-639, and pGAL-TR were
described elsewhere (23). Plasmid pGAL-erb 389-639 was
obtained by cutting pGAL-verbA with SmiaI and BclI, filling in
using the Klenow fragment of DNA-polymerase I and religating,
thereby deleting a fragment coding for a.a. 346 to 388. The
internal deletion mutant pGAL-erb 346-389/434-639 was
constructed by cutting pGAL-verbA with EcoRV and BcII, filling
in using Klenow enzyme and religating, thereby deleting a
fragment coding for a.a. 390 to 433. Plasmid pGAL-erb
346-515/615-639 was obtained by digesting pGAL-verbA with
EspI and FspI followed by religation, thereby deleting a fragment
coding for a.a. 516 to 614. pSG-hRXR containing the coding
sequence for the human RXRa was kindly provided by
H.Stunnenberg (33). The RXR coding region was first cut out
using EcoRI, filled in using Klenow enzyme and cloned into the
Eco47III site of pABGAL. Then a Hincll-HindJI fragment
coding for a.a. 235 to 462 was obtained and inserted into the
SmaI-HindI cut pABGAL to obtain plasmid pGAL-RXR
235-462.
The expression plasmids GST-erb 362-508 and GST-erb
508 -639 were constructed by insertion of the SmaIlHindIl
fragment of pGAL-erb 362-508 or pGAL-erb 508 -639,
respectively, into the vector pGEX KG (51) digested with
SmaIlHindllI.
The expression plasmid GST-GAL-erb 508-639 was obtained
by insertion of the BglHIBamHI fragment of pGAL-erb
508-639, wich was filled in using Klenow, into the vector pGEX
2TK (Pharmacia), digested with EcoRI and filled in.
Vectors for in vitro translation were obtained by insertion of
the KpnIlBamHI fragments of pGAL-erb 409-639, pGAL-erb
508 -639 and pGAL-erb 362-468/508-639 into the vector
Bluescript SK+, digested with KpnIlBamHI, and insertion of
the KpnIlHindIH fragment of pGAL-erb 362-508 into Bluescript
SK+, digested with KpnIlHindIH.
Cell culture and transfections
Ltk- cells, CVI and COSI cells were grown in DME-medium
(Gibco) supplemented with 10% fetal calf serum, 100 U/ml
penicillin and 100 pjg/ml streptomycin.
DNA transfer into CVI cells was performed using the calcium
phosphate precipitation method. Ltk- cells were transfected as
described (52). 2 x 106 cells were suspended in DNA-DEAE-
dextran solution (1 pmol reporter and 0.5 pmol expression
plasmids) and incubated for 30 min. After adding directly 7 ml
medium, cells were seeded on a 6 cm dish and grown for 36-48that GAIA fusion proteins show higher silencing effects on a UAS
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h before harvesting. Transfections were done in triplicate and
performed in at least two independent experiments. Transfections
into COSI cells were done by a similar DEAE-dextran suspen-
sion method using 6 pmole of DNA on 107 cells. After 1 h
incubation in the DNA solution, a DMSO shock was performed
for 3 min, the cells were taken up in 30 ml PBS and 10 ml
medium, spun down, seeded on a 15 cm dish and grown for 48
h before harvesting.
For hormonal induction experiments, the serum was depleted
of thyroid hormone and retinoic acid by extensive charcoal
stripping. The cells were kept for at least 24 h in depleted medium
before transfection, after transfection l0-7 M 3,5,3'-trijodthy-
ronine or 10-6 M retinoic acid was added. CAT-assays were
performed as described (53).
DNA-protein binding assays
Whole cell extracts were prepared from COSI cells transfected
with various expression vectors according to (54). Gel retardation
experiments were performed using 20000 d.p.m. of kinase-
labelled 17-mer DNA probe, 2-4 /g of whole cell extract in
an incubation mix containing 1-4 ,ug of p(dI.dC), 200 mM KCI,
2 mM DTT, 14% glycerol, 5 mM MgCl2 20 mM Hepes pH
7.7. The DNA -protein complexes formed were analysed on a
5% polyacrylamide gel in 0.5 xTBE.
Protein-protein interactions in vitro
Protein-protein interactions were assayed mainly as described
(42).
GST-fusion-proteins were expressed in E. coli BL21 cells (55).
Cells were harvested by centrifugation and resuspended in NENT
buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris pH 8.0 and
0.5% NP-40). Cells were lysed by three freeze-thaw cycles and
the cellular debris was removed by centrifugation.
Glutathione- Sepharose 4B beads were washed with NENT and
10 ,ul of beads were incubated with 100 ,ul of lysate containing
the GST-fusion protein for 30 min at room temperature.
Subsequently, the supernatant was removed and the beads were
incubated with 10% milk powder in NENT for 15 min at room
temperature. The beads were washed twice with 1 ml NENT
and once with 1 ml transcription washing buffer (20 mM Hepes
pH 7.9, 60 mM NaCl, 1 mM DTT, 6 mM MgCl2, 8%
glycerine and 0.1 mM EDTA). In vitro translated and
radiolabeled protein were obtained using a TNT-kit (Promega).
5 yd of crude lysate were incubated with the beads in 100 Al
transcription washing buffer for 1 h at room temperature. Finally
the beads were washed (5 x 1 ml of NENT) and proteins were
solubilized in SDS-loading buffer and analyzed on SDS-PAGE.
Gels were amplified with fluorigraphic reagent (Amersham) and
bands were visualised by autoradiography.
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